Clearmind Medicine Inc. (CMND) Stock Score, Valuation & Financial Research

Clearmind Medicine Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CMND

Clearmind Medicine Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.84. These figures are a research snapshot, not a buy or sell recommendation.

What Clearmind Medicine Inc. does

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Company business and revenue

Research reporting period: 2025-10-31. A research update is not a new financial filing.

How the company makes money

Clearmind Medicine Inc. is a clinical-stage pharmaceutical company that focuses on the research and development of novel psychedelic-derived therapeutics. The company aims to commercialize these compounds as regulated medicines, foods, or supplements to address underserved health problems, but it has not yet generated any revenue from operations.

Products and services

  • The company is developing a proprietary non-hallucinogenic MEAI-based oral compound, CMND-100, intended to treat alcohol use disorder.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party service providers and CROs to conduct clinical trials and research activities; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Biotechnology and Pharmaceutical Companies — The company competes with various entities in the biotechnology and pharmaceutical sectors that are also developing treatments for alcohol use disorder and other mental health conditions. Source

Business strengths to evaluate

  • Extensive intellectual property portfolio including 31 granted patents Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to continue operations Source
  • Uncertainty regarding the successful completion of clinical trials and regulatory approval Source

Sources: Company research source · Extensive intellectual property portfolio including 31 granted patents

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CMND financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.84
Market capitalization:
1.08M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.49M
Free cash flow:
USD -4.73M
Cash:
USD 12.04M
Total debt:
USD 1.8M
EPS:
USD -11.15

What stands out

  • Free cash flow is USD -4.73M, negative for the stored period.
  • The balance sheet shows USD 12.04M of cash versus USD 1.8M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.24M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CMND

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CMND fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CMND likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CMND to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CMND's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CMND

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.